Inspirna has raised $50 million in a series D financing round primarily led by Sands Capital and Vivo Capital.
Inspirna is a biopharmaceutical company. Proceeds from the financing will go toward the development of the company's small molecule inhibitor drugs RGX-202, designed to treat colorectal cancer, and RGX-104, designed to treat lung and endometrial cancer, according to a July 11 press release.
Michael Ginder of Sands Capital and Jack Nielsen of Vivo Capital are set to join Inspirna's board of directors.